Clinical Updates in Cystic Fibrosis: Applying Recent
Advances in CFTR Modulator Therapy
for Improved Patient Outcomes


A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 10, 2018 to January 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Vertex Pharmaceuticals

Description:
Cystic fibrosis (CF) is a genetic, autosomal recessive disorder caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). Cystic Fibrosis mostly affects mostly the lungs but also the pancreas, liver, kidneys and intestine. Common symptoms include difficulty breathing, sinus infections, poor growth, fatty stool, clubbing of the finger and toes, and infertility in males among others. There is no cure for cystic fibrosis, but recent treatment breakthroughs are available for about half of CF patients who have two copies of the F508del mutation in their CFTR gene. This new CFTR modulation therapeutic focuses on counteracting the damage caused by the disease, enabling patients to breath more easily and stay out of the hospital, improving outcomes and quality of life. This option is a major breakthrough in CF management, because it is the first therapy that specifically targets an important genetic mutation.

Upon Completion of this activity, participants will be able to:

  • Discuss the details of real-world outcomes for cystic fibrosis patients treated with CFTR-based therapeutics

  • Examine approved and emerging CFTR-based therapeutic options in terms of efficacy, safety, and clinical potential to improve pulmonary and non-pulmonary outcomes of patients with cystic fibrosis

  • Apply the principles of early diagnosis and early pharmaco-therapeutic intervention to the cystic fibrosis pediatric population

  • Explore current challenges with medication and treatment adherence in the cystic fibrosis patient population

  • Analyze new data related to emerging combination CFTR modulator therapies in cystic fibrosis
     

Faculty: Elliot C. Dasenbrook, MD
Cleveland Clinic Respiratory Institute
Director, Cleveland Clinic Adult Cystic Fibrosis Center

Disclosure:

Dr. Dasenbrook has no relevant financial relationships to disclose.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Vertex Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue